Trials / Completed
CompletedNCT01178073
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 610 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ambrisentan | ambrisentan (target dose: 10mg) |
| DRUG | tadalafil | tadalafil (target dose: 40mg) |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2014-07-31
- Completion
- 2014-07-31
- First posted
- 2010-08-09
- Last updated
- 2017-09-13
- Results posted
- 2015-04-28
Locations
143 sites across 14 countries: United States, Australia, Austria, Belgium, Canada, France, Germany, Greece, Italy, Japan, Netherlands, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT01178073. Inclusion in this directory is not an endorsement.